On December 15, 2021 Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, reported that each of its: President and Chief Executive Officer, Lloyd Segal; Executive Vice President and Chief Financial Officer, Steve Forte; Executive Vice-President and Chief Scientific Officer, Michael Zinda; Executive Vice-President and Chief Medical Officer, Maria Kohler; Executive Vice-President Discovery, Cameron Black; and Executive Vice President, Head of Business & Corporate Development, Kim Seth (collectively, the "Executives"), as well as certain other insiders of the Company (the "Other Insiders" and collectively with the Executives, the "Participants"), have terminated existing Automatic Securities Disposition Plans ("ASDPs") and established new ASDPs or modified existing ASDPs in accordance with applicable United States and Canadian securities legislation, including the recommended practices set forth in the recently issued Canadian Securities Administrators’ Staff Notice 55-317 ("Staff Notice 55-317") and the Company’s internal policies (Press release, Repare Therapeutics, DEC 15, 2021, View Source [SID1234597249]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

While Repare is listed on the Nasdaq Global Select Market, it is also considered a reporting issuer under the Securities Act (Québec) and is therefore announcing the foregoing establishment or amendment of the ASDPs in furtherance of the recently published guidance provided by the Canadian Securities Administrators in Staff Notice 55-317.

Under U.S. and Canadian securities laws and the Company’s trading policies, insiders of Repare are subject to limits on their ability to sell shares in the Company. The ASDPs address this issue by permitting trades to be made in accordance with pre-arranged instructions given when Participants are not in possession of any material undisclosed information.

Up to 328,681 common shares of Repare may be sold under the ASDPs implemented or modified by the Executives in the aggregate, and up to 95,320 common shares of Repare may be sold under the ASDPs implemented by the Other Insiders. The ASDPs are designed to allow for an orderly disposition of each of the Participants’ shares in Repare at prevailing market prices over the course of the 12 to 24 months that the ASDPs are expected to be in place. Sales of the common shares under the ASDPs will only commence after the Company has announced and filed its next annual financial statements for the fiscal year ended December 31, 2021, in accordance with the recent recommended practices set forth in Staff Notice 55-317.

Each Participant has provided for clear trading parameters and other instructions in writing to the independent dealers administering the ASDPs, specifying the number of securities to be sold and setting out minimum trade prices, which in most cases exceed the current trading price of the Company’s common shares, and the dates or frequencies of sales. The ASDPs prohibit the dealer administering the ASDPs from consulting with the Participants regarding any sales under the ASDPs and prohibit the Participants from disclosing to the dealer any information concerning the Company that might influence the execution of the ASDPs

The ASDPs contain meaningful restrictions on the ability of the Participants to amend, suspend or terminate the ASDPs that have the effect of ensuring that the Participants cannot benefit from material non-public information.

On December 15, 2021 AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, reported that it will report financial results for the second quarter of fiscal year 2022 before the market open on Thursday, January 6, 2022 (Press release, AngioDynamics, DEC 15, 2021, View Source [SID1234597248]). The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international) and refer to the passcode 13725681.

This conference call will also be webcast and can be accessed from the "Investors" section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available from 11:00 a.m. ET on Thursday, January 6, 2022, until 11:59 p.m. ET on Thursday, January 13, 2022. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13725681.

On December 15, 2021 Endomag reported that A novel procedure could now spare breast cancer patients an invasive surgical procedure on their lymphatic system (Press release, Endomag, DEC 15, 2021, View Source [SID1234597246]). At MD Anderson Cancer Center, doctors have pioneered the Targeted Axillary Dissection (TAD) technique, where a tiny magnetic seed is placed into patient lymph nodes known to contain cancer. Following a course of neoadjuvant chemotherapy aimed to shrink or even eradicate their cancer, prior to surgery, this novel technique allows surgeons to monitor the response of targeted lymph nodes to the chemotherapy without the need for upfront invasive surgery, such as a complete axillary dissection.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The magnetic seed, known as a Magseed allows surgeons to accurately remove the node marked prior to chemotherapy and remove it with minimal damage to healthy lymph node tissue.

Lymph nodes are a vital part of the system which helps the body to fight infection but are also the first structures breast cancer can spread to. In 40 to 75% of women, a course of chemotherapy before surgery can clear the nodes of cancer.1,2,3 However, until now, there has been no way to confirm the chemotherapy has been effective without removing a large number of lymph nodes from the underarm.

"The standard surgical approach for patients with breast cancer that has spread to the lymph nodes has been axillary lymphadenectomy (ALND), which involves removing most of the lymph nodes in the axilla," explains Dr Abigail Caudle, MD, who first pioneered the TAD technique at MD Anderson. "Unfortunately, this approach is associated with significant complications which can impact a patient’s quality of life including swelling, pain, and decreased range of motion. Some patients have an excellent response to chemotherapy and may have no disease remaining in the lymph nodes. We suspect that these patients may not benefit from having all of their lymph nodes removed, although the studies looking at this question are not yet available.

The challenge has been how to identify these patients that might benefit from less aggressive surgery. By specifically removing the exact lymph nodes that had confirmed cancer at the time of diagnosis, as well as the lymph nodes most likely to contain disease, we can now accurately assess whether there is cancer remaining in the lymph nodes and consider no further surgery if there is no evidence of cancer."

It is widely reported that up to 70% of women who have multiple nodes removed in an ALND procedure will develop complications linked to their treatment, such as the life-altering condition of lymphedema.4,5,6 Lymphedema is a condition where damage to the lymphatic system results in a build-up of lymphatic fluid in the body as a result of lymphadenectomy, causing lifelong symptoms of severe swelling, altered sensation, pain and limitations in range of motion.3. There are currently more than 10m people in the United States living with lymphedema,7 and for many patients, lymphedema is incurable.8

"There is a sea-change afoot in the treatment of breast cancer as patients become increasingly educated about the options available to prevent side effects of treatment. Foremost on this list are procedures and technologies that can prevent lymphedema—an incurable, debilitating, progressive and disfiguring swelling that can occur when the lymphatic system is damaged during surgery, radiation or chemotherapy. Women who win their battle against breast cancer routinely state that lymphedema can be worse than their cancer. Their cancer was cured. Their lymphedema is forever. In this modern world, every woman deserves the full benefits of our knowledge to mitigate onset of the life-long disease of lymphedema," explains William Repicci, LE&RN President & CEO

The Magseed marker, used by surgeons at MD Anderson, is the world’s most studied non-radioactive seed, with the technology available in over 40 countries around the world. Results from a series of past and ongoing multi-national studies 9,10 have demonstrated the ease and accuracy of marking positive lymph nodes with a Magseed marker with 100% success in surgical retrieval, negating the need for unnecessary node removal.

"This pioneering surgery exemplifies the importance of new technologies such as Magseed in moving breast cancer treatment forward." said Eric Mayes, CEO of Endomag. "These technologies have already helped over 200,000 patients globally access a better standard of cancer care. We’re committed to continually learning from physicians around the world and providing access to cutting-edge clinical applications that will make a difference to these patients for years to come.

On December 15, 2021 Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, reported that it has entered into a subscription agreement pursuant to which an affiliate of Social Capital Holdings Inc. ("Social Capital") will make a strategic C$43.4 million investment in the Company (Press release, Perimeter Medical Imaging AI, DEC 15, 2021, View Source [SID1234597242]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jeremy Sobotta, Perimeter’s Chief Executive Officer stated, "We believe Social Capital’s investment marks a transformative, pivotal event for Perimeter that will help accelerate our growth. This strategic partnering comes at a time when we are ramping up our Perimeter S-Series market development activities and commercialization efforts across the U.S., while also supporting the ongoing clinical development of our next-gen AI technologies. This financing provides us with the backing to execute upon our long-term vision to transform cancer surgery."

Chamath Palihapitiya, CEO of Social Capital, said, "Perimeter’s advanced imaging technology has the opportunity to materially improve cancer surgery outcomes. Today’s methods rely on contemporary imaging techniques, which often result in the need for additional surgery, increasing payer costs and potentially delaying subsequent treatment plans. This investment will support the commercial launch of Perimeter’s initial imaging device for breast cancer, but equally as important, we believe it can accelerate their path to become the standard of care for many other surgical applications in the future."

Social Capital has agreed to subscribe, on a non-brokered private placement basis (the "Private Placement"), for C$43.4 million in units of Perimeter at a price of C$3.00 per unit (each, a "Unit"), with each Unit consisting of one common share (each, a "Common Share") and a total of one warrant ("Warrant") to purchase an additional Common Share (a "Warrant Share"). 80% of the Warrants issued in the Private Placement will have a strike price of C$3.99 and 20% of the Warrants in the Private Placement will have a strike price of C$4.50. Half of the Warrants at each strike price will be subject to accelerated expiry if the 60-day volume weighted average trading price of Perimeter’s Common Shares is greater than the strike price during the applicable period. The other half of the Warrants will not be subject to accelerated expiry, and instead they may be exercised for cash or exercised using a cashless exercise feature at any time prior to expiry. Subject to the accelerated expiry clause described above, all Warrants will expire five years following the closing of the Private Placement.

Social Capital will also enter into an investor rights agreement with Perimeter at the closing of the Private Placement, which will provide Social Capital with the right to nominate one director to the board of Perimeter, with anti-dilution rights to participate in future financings, and with customary registration rights.

Perimeter may, but has not yet committed to, issue up to an additional C$7,000,000 million in Units on substantially the same economic terms as those issued to Social Capital.

The net proceeds of the Private Placement will be used for working capital, commercialization of Perimeter’s technology, clinical studies and the further development of Perimeter’s technology, and general corporate purposes.

About the Investment

Closing of the Private Placement is subject to the receipt of TSX Venture Exchange approval, the receipt of all necessary Perimeter shareholder approvals, and other customary closing conditions. The Private Placement will result in the creation of a new control person of Perimeter under Canadian securities laws as Social Capital will hold over 20% of the issued and outstanding shares of Perimeter, and accordingly, under TSX Venture Exchange policies, shareholder approval of the creation of the new control person will be required as a condition of closing, which will be sought by written consent. Roadmap Capital Inc., Perimeter’s largest shareholder, which owns or controls approximately 38% of the issued and outstanding Perimeter common shares, has signed a support agreement in favour of the Private Placement and has committed to sign a written consent resolution approving the Private Placement. Perimeter will provide further details on the shareholder approval in a subsequent news release. Social Capital is at arms length to Perimeter. The subscription agreement is also subject to a number of customary closing conditions, including the lack of any material adverse effect on Perimeter prior to Closing. The subscription agreement contains an outside date of January 31, 2021 for closing, which may be extended in limited circumstances. Social Capital’s board nomination and anti-dilution rights under the investor rights agreement will last so long as Social Capital holds at least 15% of the common shares of Perimeter on an undiluted basis, and Social Capital’s registration rights will last so long as Social Capital holds at least 10% of the common shares of Perimeter on an undiluted basis. A finder’s fee equal to 3% of the proceeds from the sale of Units to Social Capital is payable in respect of the Private Placement, which finders fee will be paid by issuing common shares of Perimeter ("Finder’s Shares") at $3.00 per share, subject to TSX-V approval.

The Common Shares comprising part of the Units, the Warrants and the Warrant Shares (if such Warrant Shares are issued before the date that is four months and one day following the applicable Closing Date) and the Finder’s Shares shall be subject to a hold period ending on the date that is four months and one day following the applicable Closing Date.

On December 15, 2021 Paige, the global leader in AI-based diagnostic software in pathology, reported that University of Louisville (UofL) Health, a leading academic health system based in Louisville, Kentucky, has deployed a full suite of Paige AI-enabled digital pathology software to improve diagnostic confidence, efficiency, and patient care during routine cancer diagnosis (Press release, Paige AI, DEC 15, 2021, View Source [SID1234597240]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

UofL Health is one of the first health systems in the U.S. to implement Paige Prostate, the first and only AI-based pathology product to receive FDA approval for in vitro diagnostic (IVD) use in detecting cancer in prostate biopsies. UofL Health will also deploy Paige’s FullFocus as their digital pathology case management tool and digital pathology image viewer, and Paige Breast to elevate pathologists’ ability to diagnose cancer.

With cancer cases on the rise globally, AI technologies have the potential to help pathologists work more confidently and efficiently. AI can act as a second pair of eyes for pathologists, helping them to quickly spot very small, almost imperceptible regions of cancer in a tissue sample that may be challenging to recognize with the naked eye. This can translate into better accuracy in cancer diagnosis and ultimately better clinical management for patients.

"We are proud to be one of the first health systems in the U.S. to adopt an AI-enabled digital pathology software platform which offers an enhanced look at tissues and acts as a built-in second opinion in our routine diagnostic processes," said Dibson Dibe Gondim, M.D., Director of Pathology Informatics, Assistant Professor of Pathology and Laboratory Medicine, Associate Residency Program Director of Anatomic Pathology, and Director of Genitourinary Pathology at the University of Louisville School of Medicine. "Leveraging the Paige Platform and AI tools, such as Paige Prostate, will help us increase efficiency and diagnostic confidence for our patients and improve our pathology workflows."

Additionally, UofL Health will leverage Paige’s Software Development Kit, an open platform that enables institutions to deploy customized laboratory developed tests for digital pathology, to deploy AI algorithms to assist in operational efficiencies and image analysis that were developed in-house.

"Completing our deployment at University of Louisville Health is an exciting milestone for Paige as we help hospital systems adopt digital, AI-based technologies to make their existing workflows more accurate and efficient," said Andy Moye, Ph.D., Chief Commercial Officer at Paige. "We are proud to offer a robust portfolio of AI-enabled digital pathology technologies backed by the FDA. We are also excited to see how the University of Louisville is utilizing the Paige Software Development Kit to achieve near-term clinical impact, and we hope this will be the first of many research applications adopting our open technology to improve patient care."

Outside of the U.S., Paige Prostate is CE-marked for use in laboratories and hospitals in the European Economic Area, Switzerland and the UK. FullFocus is FDA cleared and CE-marked. The products are otherwise available for research use only in other territories.

About Paige